The advent of pharmacogenomics in drug development heralds a paradigm shift within the pharmaceutical sector. This evolution is driven by the increasing prominence of personalized medicine, where a patient's genetic profile dictates the choice of medication and dosage. This approach is pivotal in enhancing treatment efficacy. The global pharmaceutical market, valued at approximately $825 billion, confronts significant hurdles. Notably, up to 40% of daily medications prove ineffective, resulting in financial losses of up to $400 billion1.
This scenario has prompted pharmaceutical entities to invest heavily in pharmacogenomic research. Such efforts are aimed at leveraging genetic variations to predict drug responses. Currently, only 10% of FDA-approved drugs (around 200) incorporate pharmacogenomic data in their labels, underscoring the vast potential for expansion in this field2. The pharmaceutical industry must now grapple with the clin...
_____
If you are a member of our Association, please log in below to continue reading our exclusive content.
Not a member yet? Discover the benefits of joining our network and gain access to exclusive content like this for only $29.95 per month. Learn More and Sign Up
